Abstract |
The R- CHOP regimen has been found to improve the outcome of diffuse large B-cell lymphoma (DLBCL). However, it does not provide a satisfactory treatment outcome in the high-risk group. We previously administered the CyclOBEAP regimen to patients with DLBCL, and reported its safety and efficacy. The R- CyclOBEAP regimen was administered over a total period of 12 weeks, and rituximab 375 mg/m(2) was given every 2 weeks. There were 101 eligible patients. CR was achieved in 96 patients (95%). The 5-year overall survival (OS) rate was 85% and progression-free survival (PFS) rate was 76%. When the patients were divided according to the IPI, the 5-year OS and PFS rates did not significantly differ among the risk groups. The 5-year PFS of the germinal centre B-cell group was 80% and that of the non-GCB group was 74% (NS). Univariate analysis showed that the presence of B symptoms, extranodal lesions >or=2, and sIL-2R were significant poor prognostic factors. Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients. The addition of rituximab to CyclOBEAP therapy may enhance the effect of CyclOBEAP therapy for DLBCL.
|
Authors | Nozomi Niitsu, Mika Kohri, Yuki Hagiwara, Ken Tanae, Naoki Takahashi, Masami Bessho, Masataka Okamoto |
Journal | Hematological oncology
(Hematol Oncol)
Vol. 28
Issue 2
Pg. 68-74
(Jun 2010)
ISSN: 1099-1069 [Electronic] England |
PMID | 20235332
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Copyright | (c) 2010 John Wiley & Sons, Ltd. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Bleomycin
- Rituximab
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Prednisolone
|
Topics |
- Adult
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Bleomycin
(administration & dosage, adverse effects)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Disease-Free Survival
- Doxorubicin
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Kaplan-Meier Estimate
- Lymphoma, Large B-Cell, Diffuse
(drug therapy)
- Male
- Middle Aged
- Neutropenia
(chemically induced)
- Prednisolone
(administration & dosage, adverse effects)
- Prognosis
- Rituximab
- Thrombocytopenia
(chemically induced)
- Treatment Outcome
- Vincristine
(administration & dosage, adverse effects)
- Young Adult
|